Cell Culture Company (C3) Deal Targets Pancreatic Cancer

Cell Culture Company (C3), a biopharmaceutical developer and manufacturer, has entered into an agreement with a China-based joint venture to produce a clinical-grade antibody-based therapeutic vaccine targeting pancreatic cancer.

OncoVent, a joint venture between Shenzhen Hepalink Pharmaceutical Co. and Canada-based OncoQuest, began negotiations with C3 after its drug candidate had produced positive pre-clinical data for a combinatory immunotherapy targeting pancreatic cancer. C3 was ultimately awarded the contract and will complete the work at its Minneapolis-based cGMP bioproduction facility.

"C3 was chosen because of its ability to meet aggressive timelines, while providing the highest levels of expertise and quality," said OncoVent CEO, Dr. Y. Eric Shi. "We hope this is the beginning of a long relationship that results in saving many lives."

C3 is headquartered in a 33,000 square foot facility that houses corporate offices, bioreactor manufacturing operations, GMP-compliant laboratory space, and a distribution center.

“It's an honor to be selected to support OncoVent’s immunotherapy development,” said Christiaan Engstrom, President at C3. “We look forward to leading the production of a product we hope will have global impact.”